Skip to main content
Egyptian Rheumatology and Rehabilitation
Download PDF

C-telopeptide of type I collagen (CTX-1) in premenopausal Egyptian women with fibromyalgia syndrome

Egyptian Rheumatology and Rehabilitation volume 42, pages 80–86 (2015)Cite this article

Abstract

Introduction

The majority of the fibromyalgia syndrome (FMS) patients do not exercise regularly and their physical fitness is low. Physical inactivity accelerates bone loss. This suggests that FMS patients are at risk in terms of osteoporosis. The aim of this study was to measure serum C-telopeptide of type I collagen (CTX-1) as a marker of bone resorption in premenopausal women with FMS.

Patients and methods

A total of 100 premenopausal female patients with FMS diagnosed according to the American College of Rheumatology (ACR) criteria 1990 and 50 healthy women were chosen to serve as the control group. Serum CTX-1 levels were measured using beta-CrossLaps Roche Elecsys.

Results

The serum CTX-1 level was significantly higher in patients with FMS compared with the control group. The mean serum CTX-1 in FMS patients was 340.2 ± 112.6 pg/ml compared with 283.6 ± 113.1 pg/ml in controls (P = 0.004). The serum CTX-1 level was positively correlated with the visual analogue scale(VAS) of pain (P = 0.028), the VAS of fatigue (P = 0.031), the VAS of global severity (P = 0.016), the VAS of anxiety (P = 0.013), the Health Assessment Questionnaire score (P = 0.022), the Fibromyalgia Impact Questionnaire (P = 0.010), the Beck Depression Inventory (P = 0.007), the tender points count (P = 0.003), the tender points score (P = 0.004), and the Pittsburg Sleep Quality Index (P = 0.021). The mean serum CTX-1 level was also significantly higher in FMS patients with postexertion pain (P = 0.010), confusion (P = 0.025), dizziness (P = 0.012), depression (P = 0.029), mood disturbance (P = 0.018), anxiety (P = 0.030), short memory difficulties (P = 0.017), and sleep disturbance (P = 0.028) than in those without these symptoms.

Conclusion

We found a significant increase in serum CTX-1 in FMS patients compared with controls, and this was correlated with the disease severity. Increased CTX-1 may lead to the early development of osteoporosis. More comprehensive and detailed studies are needed to determine the exact role of CTX-1 in FMS.

References

  1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria committee. Arthritis Rheum 1990; 33:160–172

    Article  CAS  Google Scholar 

  2. Kroger H, Tuppurainen M, Honkanen R, Alhava E, Saarikoski S. Bone mineral density and risk factors for osteoporosis – a population-based study of 1600 perimenopausal women. Calcif Tissue Int 1994; 55:1–7.

    Article  CAS  Google Scholar 

  3. Cizza G, Primma S, Coyle M, Gourgiotis L, Csako G. Depression and osteoporosis: a research synthesis with meta-analysis. Horm Metab Res 2010; 42:467–482.

    Article  CAS  Google Scholar 

  4. Blake GM, Fogelman I, Blake GM, Fogelman I, Blake GM, Fogelman I. Monitoring treatment for osteoporosis by using bone densitometry. Semin Nucl Med 2001; 31:212–222.

    Article  CAS  Google Scholar 

  5. Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 1997; 7:390–406.

    Article  CAS  Google Scholar 

  6. Ofluoglu D, Karadag-Saygi E, Canbulat C, Gunduz OH, Kul-Panza E, Akyuz G. Early effect of nasal salmon calcitonin on the bone marker Crosslaps. Rheumatol Int 2006; 26:288–291.

    Article  CAS  Google Scholar 

  7. Brown JP, Josse RG, Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002; 167(Suppl): S1– S34.

    PubMed  PubMed Central  Google Scholar 

  8. Herrmann M, Seibel MJ. The amino- and carboxyterminal cross-linked telopeptides of collagen type I, NTX-I and CTX-I: a comparative review. Clin Chim Acta 2008; 393:57–75.

    Article  CAS  Google Scholar 

  9. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J, Committee of Scientific Advisors of the International Osteoporosis Foundation. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 2000; 11 : Suppl 6:S2-S17.

    Article  Google Scholar 

  10. Wekre LL, Eriksen EF, Falch JA. Bone mass, bone markers and prevalence of fractures in adults with osteogenesis imperfecta. Arch Osteoporos 2011; 6:31–38.

    Article  Google Scholar 

  11. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010; 62:600–610.

    Article  Google Scholar 

  12. Huskisson EC. measurement of pain. Lancet 1974; 2:1127–31.

    Article  CAS  Google Scholar 

  13. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991; 18:728–733.

    CAS  PubMed  Google Scholar 

  14. Salen BA, Spangfort EV, Nygren AL, Nordemar R. The disability rating index: an instrument for the assessment of disability in clinical sitting. J Clin Epidemiol 1994; 47:1423–1435.

    Article  CAS  Google Scholar 

  15. Fries JF, Spitz PW, Karines RG, Holman HR. Measurement patient outcome in arthritis. Arthritis Rheum 1980; 23:137–145.

    Article  CAS  Google Scholar 

  16. Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28:193–213.

    Article  CAS  Google Scholar 

  17. Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin Psychol Rev 1988; 8:77–100.

    Article  Google Scholar 

  18. Nørregaard J, Bülow PM, Lykkegaard JJ, Mehlsen J, Danneskiold-Samsøoe B. Muscle strength, working capacity and effort in patients with fibromyalgia. Scand J Rehabil Med 1997; 29:97–102.

    PubMed  Google Scholar 

  19. Riis BJ. Biochemical markers of bone turnover. II: Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993; 95(5A): 17S–21S.

    Article  CAS  Google Scholar 

  20. Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med 2006; 119(Suppl 1): S25–S25S31.

    Article  Google Scholar 

  21. El Maghraoui A, Tellal S, Chaouir S, Lebbar K, Bezza A, Nouijai A, et al. Bone turnover markers, anterior pituitary and gonadal hormones, and bone mass evaluation using quantitative computed tomography in ankylosing spondylitis. Clin Rheumatol 2005; 24:346–351.

    Article  Google Scholar 

  22. Achemlal L, Tellal S, Rkiouak F, Nouijai A, Bezza A, Derouiche el M, et al. Bone metabolism in male patients with type 2 diabetes. Clin Rheumatol 2005; 24:493–496.

    Article  Google Scholar 

  23. Garnero P, Ferreras M, Karsdal MA, Nicamhlaoibh R, Risteli J, Borel O, et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 2003;18:859–867.

    Article  CAS  Google Scholar 

  24. Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, et al. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67:353–357.

    Article  CAS  Google Scholar 

  25. Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garnero P, Griesmacher A, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 2011; 22:391–420.

    Article  CAS  Google Scholar 

  26. Lee J, Vasikaran S. Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis. Ann Lab Med2012; 32:105–112.

    Article  CAS  Google Scholar 

  27. Appelboom T, Schoutens A. High bone turnover in fibromyalgia. Calcif Tissue Int 1990; 46:314–317.

    Article  CAS  Google Scholar 

  28. El Maghraoui A, Tellal S, Achemlal L, Nouijai A, Ghazi M, Mounach A, et al. Bone turnover and hormonal perturbations in patients with fibromyalgia. Clin Exp Rheumatol 2006; 24:428–431.

    CAS  PubMed  Google Scholar 

  29. Jacobsen S, Gam A, Egsmose C, Olsen M, Danneskiold-Samsøe B, Jensen GF. Bone mass and turnover in fibromyalgia. J Rheumatol 1993; 20:856–859.

    CAS  PubMed  Google Scholar 

  30. Ribel-Madsen S, Christgau S, Gronemann ST, Bartels EM, Danneskiold-Samsøe B, Bliddal H. Urinary markers of altered collagen metabolism in fibromyalgia patients. Scand J Rheumatol 2007; 36:470–477.

    Article  CAS  Google Scholar 

  31. Sprott H, Müller A, Heine H. Collagen cross-links in fibromyalgia syndrome. Z Rheumatol 1998; 57:Suppl 2:52–55.

    Article  Google Scholar 

  32. Mateos F, Valero C, Olmos JM, Casanueva B, Castillo J, Martínez J, et al. Bone mass and vitamin D levels in women with a diagnosis of fibromyalgia. Osteoporos Int 2014; 25:525–533.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology and Rehabilitation, Faculty of Medicine, Mansoura University, Mansoura, Egypt

    Shereen Mohamed Olama MD & Tamer O. ElSaid

  2. Clinical Pathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt

    Mohammad M. El-Arman

  3. Department of Rheumatology, Faculty of Medicine, Northern Border University, Arar, Saudi Arabia

    Shereen Mohamed Olama MD

Authors
  1. Shereen Mohamed Olama MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tamer O. ElSaid
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohammad M. El-Arman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shereen Mohamed Olama MD.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Olama, S.M., ElSaid, T.O. & El-Arman, M.M. C-telopeptide of type I collagen (CTX-1) in premenopausal Egyptian women with fibromyalgia syndrome. Egypt Rheumatol Rehabil 42, 80–86 (2015). https://doi.org/10.4103/1110-161X.157867

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/1110-161X.157867

Keywords